| scholarly article | Q13442814 |
| P50 | author | Gianluca Gaidano | Q30303486 |
| Davide Rossi | Q89878155 | ||
| P2093 | author name string | Simon C Robson | |
| Richard R Furman | |||
| Giorgio Inghirami | |||
| Sara Serra | |||
| Shih-Shih Chen | |||
| Nicholas Chiorazzi | |||
| Marta Coscia | |||
| Cinzia Bologna | |||
| Davide Brusa | |||
| Silvia Deaglio | |||
| Tiziana Vaisitti | |||
| Valentina Audrito | |||
| Francesca Arruga | |||
| Ozren Jaksic | |||
| Roberta Buonincontri | |||
| P2860 | cites work | HIF-1: upstream and downstream of cancer metabolism | Q24647482 |
| Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 | ||
| Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury | Q24796780 | ||
| A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment | Q26749571 | ||
| Fueling immunity: insights into metabolism and lymphocyte function | Q27025284 | ||
| HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression | Q27025886 | ||
| Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage | Q28214799 | ||
| Chronic lymphocytic leukemia | Q28236621 | ||
| Ecto-enzyme and signaling functions of lymphocyte CD73 | Q28268472 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase | Q28473067 | ||
| Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice | Q28584939 | ||
| Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104 | Q28741513 | ||
| Macrophage plasticity and polarization: in vivo veritas | Q29547620 | ||
| Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics | Q29615944 | ||
| Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation | Q30431948 | ||
| Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis | Q33667612 | ||
| In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells | Q33830733 | ||
| Extracellular adenosine-mediated modulation of regulatory T cells | Q33878542 | ||
| The role of the transcription factor CREB in immune function | Q33920635 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes | Q34128389 | ||
| Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia | Q34268301 | ||
| Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia | Q34797847 | ||
| Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia | Q34842221 | ||
| Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis | Q34936598 | ||
| A2A adenosine receptor protects tumors from antitumor T cells. | Q35016529 | ||
| A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease | Q35029969 | ||
| Molecular regulation of effector and memory T cell differentiation | Q35283304 | ||
| Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. | Q35698535 | ||
| Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. | Q35765467 | ||
| CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death | Q35930211 | ||
| The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells | Q36165173 | ||
| Immunological mechanisms of the antitumor effects of supplemental oxygenation | Q36269330 | ||
| Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease | Q36575943 | ||
| Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process | Q36867167 | ||
| The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. | Q36892616 | ||
| Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants | Q36904140 | ||
| Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. | Q37091230 | ||
| HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment | Q37097867 | ||
| HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations | Q37123874 | ||
| Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors | Q37157425 | ||
| Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells | Q37209070 | ||
| The microenvironment in mature B-cell malignancies: a target for new treatment strategies | Q37563816 | ||
| HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. | Q37581909 | ||
| Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury. | Q37625454 | ||
| Extracellular adenosine triphosphate and adenosine in cancer. | Q37775889 | ||
| Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment | Q37917741 | ||
| Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future | Q37975129 | ||
| ENTPD1/CD39 is a promising therapeutic target in oncology | Q38023121 | ||
| Regulation of CLL survival by hypoxia-inducible factor and its target genes | Q38030217 | ||
| The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies | Q38135644 | ||
| Pyruvate kinase M2 and cancer: an updated assessment | Q38205677 | ||
| Moonlighting adenosine deaminase: a target protein for drug development | Q38220597 | ||
| Targeting cancer-derived adenosine: new therapeutic approaches | Q38230818 | ||
| Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia | Q38232483 | ||
| CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis | Q38289911 | ||
| Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment | Q38550810 | ||
| Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1. | Q39721664 | ||
| GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. | Q40610106 | ||
| Metabolic plasticity in CLL: adaptation to the hypoxic niche | Q41094283 | ||
| Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells | Q44225915 | ||
| T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response | Q45292627 | ||
| Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia | Q46874661 | ||
| Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. | Q51686376 | ||
| Nurse like cells: chronic lymphocytic leukemia associated macrophages. | Q53644676 | ||
| CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential | Q61640131 | ||
| Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids | Q72258984 | ||
| Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes | Q79174323 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| leukemia | Q29496 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| P304 | page(s) | 47-61 | |
| P577 | publication date | 2016-11-29 | |
| P1476 | title | Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment | |
| P478 | volume | 1 |
| Q90704170 | Adenosinergic signaling as a target for natural killer cell immunotherapy |
| Q90893993 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies |
| Q46011813 | Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. |
| Q91753700 | HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia |
| Q90189895 | Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions |
| Q39169789 | Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia |
| Q92556947 | NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer |
| Q92012963 | Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups |
| Q55260280 | Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy. |
| Q60921609 | Targeting Adenosine Receptor Signaling in Cancer Immunotherapy |
| Q52323624 | Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche? |
Search more.